| Title |
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, September 2020
|
| DOI | 10.1158/1535-7163.mct-19-1004 |
| Pubmed ID | |
| Authors |
Lillian Skidmore, Sukumar Sakamuri, Nick A Knudsen, Amha Gebre Hewet, Snezana Milutinovic, Wisam Barkho, Sandra Lyn Biroc, Jessica Kirtley, Robin Marsden, Kristine Storey, Ianina Lopez, Wayne Yu, Shiao-Yan Fang, Sulan Yao, Yi Gu, Feng Tian |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 73 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 15% |
| Researcher | 9 | 12% |
| Student > Ph. D. Student | 6 | 8% |
| Student > Postgraduate | 4 | 5% |
| Student > Master | 4 | 5% |
| Other | 8 | 11% |
| Unknown | 31 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Chemistry | 7 | 10% |
| Medicine and Dentistry | 7 | 10% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Agricultural and Biological Sciences | 4 | 5% |
| Other | 9 | 12% |
| Unknown | 33 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 28. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2023.
All research outputs
#1,211,102
of 23,462,326 outputs
Outputs from Molecular Cancer Therapeutics
#118
of 3,913 outputs
Outputs of similar age
#34,925
of 400,869 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#3
of 53 outputs
Altmetric has tracked 23,462,326 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,913 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,869 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 53 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.